• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    BioMarin to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Tuesday, October 29, 2024, at 4:30pm ET

    10/16/24 8:30:00 AM ET
    $BMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BMRN alert in real time by email

    SAN RAFAEL, Calif., Oct. 16, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Tuesday, October 29, 2024, at 4:30 p.m. ET to discuss third quarter 2024 financial results and provide a general business update.

    BioMarin Pharmaceutical logo (PRNewsfoto/BioMarin Pharmaceutical Inc.)

    Dial-in Number 

    U.S. / Canada Dial-in Number: 888-596-4144

    International Dial-in Number: 646-968-2525

    Conference Call ID: 4980126

    U.S. / Canada Replay Dial-in Number: 800-770-2030

    International Replay Dial-in Number: 609-800-9909

    Playback ID: 4980126

    Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, https://investors.biomarin.com/. A replay of the call will be archived on the site for one week following the call.

    About BioMarin

    Founded in 1997, BioMarin is a global biotechnology company dedicated to transforming lives through genetic discovery. The company develops and commercializes targeted therapies that address the root cause of genetic conditions. BioMarin's unparalleled research and development capabilities have resulted in eight transformational commercial therapies for patients with rare genetic disorders. The company's distinctive approach to drug discovery has produced a diverse pipeline of commercial, clinical, and pre-clinical candidates that address a significant unmet medical need, have well-understood biology, and provide an opportunity to be first-to-market or offer a substantial benefit over existing treatment options. For additional information, please visit www.biomarin.com.

    Contacts:



    Investors     

    Media

    Traci McCarty   

    Marni Kottle

    BioMarin Pharmaceutical Inc.   

    BioMarin Pharmaceutical Inc.

    (415) 455-7558   

    (650) 374-2803

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/biomarin-to-host-third-quarter-2024-financial-results-conference-call-and-webcast-on-tuesday-october-29-2024-at-430pm-et-302277174.html

    SOURCE BioMarin Pharmaceutical Inc.

    Get the next $BMRN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Q&A

    New
    • Who will host the conference call for BioMarin's third quarter financial results?

      Alexander Hardy, President and CEO of BioMarin Pharmaceutical Inc.

    • When is the conference call scheduled?

      The conference call will be held on Tuesday, October 29, 2024, at 4:30 p.m. ET.

    • What are the dial-in numbers for the conference call?

      The U.S. / Canada dial-in number is 888-596-4144, and the international dial-in number is 646-968-2525.

    • How can interested parties listen to the conference call?

      Interested parties can access a live audio webcast via the investor section of BioMarin's website.

    • What is the focus of BioMarin Pharmaceutical Inc. and what have they achieved?

      BioMarin Pharmaceutical Inc. specializes in developing targeted therapies for genetic conditions and has eight commercial therapies for rare genetic disorders.

    Recent Analyst Ratings for
    $BMRN

    DatePrice TargetRatingAnalyst
    2/24/2025$98.00Perform → Outperform
    Oppenheimer
    11/15/2024$95.00Outperform
    Wolfe Research
    10/30/2024Outperform → Mkt Perform
    William Blair
    10/10/2024$79.00Outperform
    Raymond James
    8/20/2024$94.00 → $110.00Mkt Perform → Outperform
    Bernstein
    5/17/2024$104.00 → $72.00Outperform → Neutral
    Robert W. Baird
    5/14/2024$113.00Outperform
    Evercore ISI
    11/15/2023$100.00Overweight
    Wells Fargo
    More analyst ratings

    $BMRN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BioMarin Pharmaceutical upgraded by Oppenheimer with a new price target

      Oppenheimer upgraded BioMarin Pharmaceutical from Perform to Outperform and set a new price target of $98.00

      2/24/25 8:15:22 AM ET
      $BMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wolfe Research initiated coverage on BioMarin Pharmaceutical with a new price target

      Wolfe Research initiated coverage of BioMarin Pharmaceutical with a rating of Outperform and set a new price target of $95.00

      11/15/24 7:39:24 AM ET
      $BMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioMarin Pharmaceutical downgraded by William Blair

      William Blair downgraded BioMarin Pharmaceutical from Outperform to Mkt Perform

      10/30/24 6:37:15 AM ET
      $BMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMRN
    SEC Filings

    See more
    • SEC Form 8-K filed by BioMarin Pharmaceutical Inc.

      8-K - BIOMARIN PHARMACEUTICAL INC (0001048477) (Filer)

      5/22/25 4:05:34 PM ET
      $BMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC TO-C filed by BioMarin Pharmaceutical Inc.

      SC TO-C - BIOMARIN PHARMACEUTICAL INC (0001048477) (Subject)

      5/16/25 7:59:36 AM ET
      $BMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioMarin Pharmaceutical Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - BIOMARIN PHARMACEUTICAL INC (0001048477) (Filer)

      5/16/25 7:54:33 AM ET
      $BMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMRN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BioMarin Announces Completion of Acquisition of Inozyme

      SAN RAFAEL, Calif., July 1, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) said today that it completed the previously announced agreement to acquire Inozyme Pharma, Inc. (NASDAQ:INZY) for $4.00 per share in an all-cash transaction worth approximately $270 million. The acquisition will strengthen BioMarin's enzyme therapies portfolio, adding a late-stage enzyme replacement therapy, INZ-701. The medicine is currently being developed for the treatment of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) Deficiency, a rare, serious and progressive genetic condition that affects blood vessels, soft tissues and bones. On May 16, 2025, BioMarin and Inozyme announced tha

      7/1/25 8:45:00 AM ET
      $BMRN
      $INZY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioMarin Presents Five-Year Phase 3 Results Reinforcing Long-Term Efficacy and Safety of ROCTAVIAN® (valoctocogene roxaparvovec-rvox) at International Society on Thrombosis and Haemostasis 2025 Congress

      Data from longest and largest hemophilia gene therapy study demonstrates sustained factor VIII expression and bleed control, with 81.3% of individuals remaining off prophylaxis No new safety signals observed SAN RAFAEL, Calif., June 24, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced new data underscoring the long-term efficacy and safety of ROCTAVIAN® (valoctocogene roxaparvovec-rvox) were presented at the 33rd Congress of the International Society on Thrombosis and Haemostasis (ISTH) in Washington, D.C., June 21-25, 2025. The Phase 3 GENEr8-1

      6/24/25 9:00:00 AM ET
      $BMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma

      Acquisition is Strong Strategic Fit for BioMarin, Adding INZ-701, a Phase 3 Enzyme Replacement Therapy Being Developed for Treatment of ENPP1 Deficiency First Pivotal Data Readout in Children Expected in Early 2026 with Potential Launch in 2027; Additional Clinical Programs to Expand to Patients of all Ages  Potential First-in-Disease Treatment for ENPP1 Deficiency Conference Call and Webcast Scheduled Today at 8:45 a.m. ET SAN RAFAEL, Calif. and BOSTON, May 16, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) and Inozyme Pharma, Inc. (NASDAQ:INZY) announced today that BioMarin has entered into a definitive agreement to acquire Inozyme for $4.00 per share in an all-cash transa

      5/16/25 7:30:00 AM ET
      $BMRN
      $INZY
      Biotechnology: Pharmaceutical Preparations
      Health Care